PETS

PetMeds is in a full-blown operational unwind, not a cyclical dip. Revenue has fallen three straight years from the FY2024 peak of $274M to $179M in FY2026 — a -21.1% YoY drop — while the FY2026 net loss of $57.3M (diluted EPS -$2.74) swung from a modest loss the year prior. The tell is that operating income (-$58.7M) is worse than gross profit ($50.2M) is positive, meaning operating expenses swallowed the entire gross margin and then some. That gap between the $57.3M net loss and the $28.4M operating cash outflow points squarely at a large non-cash charge — consistent with the 10-K's emphasis on annual goodwill/intangible impairment testing, i.e. the PetCareRx acquisition being written down. Either way, the equity base collapsed 66% to $28.9M and retained earnings fell 86% to $9.26M.

The binding constraint is liquidity. Operations consumed $28.4M of cash in FY2026, yet only $21.4M of cash remains after a 60.9% drawdown, and capex still ran $4.62M. At anything near this burn rate the company has under a year of runway before it must raise capital, cut deeper, or breach its working-capital position — current liabilities ($52.0M) already exceed current assets ($43.6M) for a current ratio below 1.0. The 88% dividend cut (to a token $21K) confirms management is scrambling to preserve cash. This is what a cash-flow-negative retailer looks like heading into a financing event; the outcome for equity holders (dilution, or worse) is genuinely unknowable from the data provided.